3-9453732-A-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM2PP3PP5_Very_Strong
The NM_001080517.3(SETD5):c.2347-7A>G variant causes a splice region, splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 31)
Consequence
SETD5
NM_001080517.3 splice_region, splice_polypyrimidine_tract, intron
NM_001080517.3 splice_region, splice_polypyrimidine_tract, intron
Scores
2
Splicing: ADA: 0.9995
2
Clinical Significance
Conservation
PhyloP100: -0.397
Genes affected
SETD5 (HGNC:25566): (SET domain containing 5) This function of this gene has yet to be determined but based on sequence similarity to other SET domain proteins it may function as a histone methyltransferase. Mutations in this gene have been associated with an autosomal dominant form of intellectual disability. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 11 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
Variant 3-9453732-A-G is Pathogenic according to our data. Variant chr3-9453732-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 280376.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-9453732-A-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SETD5 | NM_001080517.3 | c.2347-7A>G | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | ENST00000402198.7 | NP_001073986.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SETD5 | ENST00000402198.7 | c.2347-7A>G | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | 5 | NM_001080517.3 | ENSP00000385852 | P4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 genomes
Cov.:
31
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 31
GnomAD4 genome
Cov.:
31
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Lifecell International Pvt. Ltd | - | A Heterozygous Splice site region variant c.2347-7A>G in Exon 16 of the SETD5 gene that results in the amino acid substitution was identified. The observed variant is novel in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect of the protein and REVEL score . Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic (ClinVar ID: 280376). Published functional studies demonstrate a damaging effect (insertion of a 6-bp intronic sequence causing a premature stop codon and nonsense-mediated mRNA decay). Patients clinical presentations included cognitive delay, growth retardation, autism spectrum disorder, attention deficit hyperactivity disorder, unsteady gait, heart defects, and craniofacial dysmorphism (Kobayashi Y et al., 2016, Powis Z et al., 2018). Based on the above evidence this variant has been classified as Pathogenic according to the ACMG guidelines. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Dec 21, 2023 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with intellectual developmental disorder, autosomal dominant 23 (MIM#615761). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Some mildly affected parents with the same SETD5 variant as their more severely affected children have been reported (PMID: 28881385, 27375234). (I) 0210 - Splice site variant proven to affect splicing of the transcript with a known effect on protein sequence. Published functional studies using RT-PCR and next generation sequencing on a patient-derived lymphoblastoid cell line identified a 6bp insertion within the intronic sequence, introducing a premature stop codon and resulting in subsequent nonsense-mediated mRNA decay (PMID: 26482601). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported as pathogenic in at least 11 individuals with SETD5-related features, six of which were confirmed de novo (ClinVar, PMIDs: 26482601, 28881385). (SP) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed) (by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Jun 26, 2020 | The de novo heterozygous c.2347-7A>G splice region variant identified in the SETD5 gene has been reported in at least 4 individuals affected with a neurological disorder [PMID: 26482601; PMID:28881385]. Patients' clinical presentations included cognitive delay, growth retardation, autism spectrum disorder, attention deficit hyperactivity disorder, unsteady gait, heart defects, and craniofacial dysmorphism [PMID: 26482601; PMID:28881385]. Analysis of cDNA obtained from a patient derived lymphoblastoid cell lineshowed that this splice region variant introduces premature stop codon and the mutant mRNA is subjected to nonsense mediated decay [PMID: 26482601]. This variant has been reported as Pathogenic in ClinVar database by two independent laboratories [Variation ID:280376]. This variant is absent from gnomAD suggesting it is an extremely rare allele in the populations represented in this database. Based on the available evidence, the de novo c.2347-7A>G splice region variant identified in the SETD5 gene is reported as Pathogenic. - |
not provided Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 25, 2022 | Published functional studies demonstrate a damaging effect (insertion of a 6-bp intronic sequence causing a premature stop codon and nonsense-mediated mRNA decay) (Kobayashi et al., 2016); Not observed in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 33490948, 26482601, 28881385) - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 04, 2016 | - - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genetics Laboratory, UDIAT-Centre Diagnòstic, Hospital Universitari Parc Tauli | Apr 26, 2021 | PVS1_very strong;PS3_strong;PM2_supporting;PM6_moderate;BP4_supporting - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: 1
DS_AL_spliceai
Position offset: 7
Find out detailed SpliceAI scores and Pangolin per-transcript scores at